Literature DB >> 19475583

A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial.

Huei-Ting Tsai1, Stanley N Caroff, Del D Miller, Joseph McEvoy, Jeffrey A Lieberman, Kari E North, T Scott Stroup, Patrick F Sullivan.   

Abstract

Tardive dyskinesia (TD) is a movement disorder characterized by involuntary oro-facial, limb, and truncal movements. As a genetic basis for inter-individual variation is assumed, there have been a sizeable number of candidate gene studies. All subjects met diagnostic criteria for schizophrenia and were randomized to receive antipsychotic medications as participants in the Clinical Antipsychotic Trials of Intervention Effectiveness project (CATIE). TD was assessed via the Abnormal Involuntary Movement Scale at regular intervals. Probable TD was defined as meeting Schooler-Kane criteria at any scheduled CATIE visit (207/710 subjects, 29.2%). A total of 128 candidate genes were studied in 710 subjects-2,580 SNPs in 118 candidate genes selected from the literature (e.g., dopamine, serotonin, glutamate, and GABA pathways) and composite genotypes for 10 drug-metabolizing enzymes. No single marker or haplotype association reached statistical significance after adjustment for multiple comparisons. Thus, we found no support for either novel or prior associations from the literature. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19475583      PMCID: PMC3894657          DOI: 10.1002/ajmg.b.30981

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  25 in total

1.  A haplotype map of the human genome.

Authors: 
Journal:  Nature       Date:  2005-10-27       Impact factor: 49.962

2.  Guilt beyond a reasonable doubt.

Authors:  David Altshuler; Mark Daly
Journal:  Nat Genet       Date:  2007-07       Impact factor: 38.330

3.  Estimation of the multiple testing burden for genomewide association studies of nearly all common variants.

Authors:  Itsik Pe'er; Roman Yelensky; David Altshuler; Mark J Daly
Journal:  Genet Epidemiol       Date:  2008-05       Impact factor: 2.135

4.  PLINK: a tool set for whole-genome association and population-based linkage analyses.

Authors:  Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham
Journal:  Am J Hum Genet       Date:  2007-07-25       Impact factor: 11.025

5.  Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients.

Authors:  C C Zai; V De Luca; R W Hwang; A Voineskos; D J Müller; G Remington; J L Kennedy
Journal:  Mol Psychiatry       Date:  2007-09       Impact factor: 15.992

6.  Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions.

Authors:  P R Bakker; P N van Harten; J van Os
Journal:  Mol Psychiatry       Date:  2008-01-08       Impact factor: 15.992

7.  TAMAL: an integrated approach to choosing SNPs for genetic studies of human complex traits.

Authors:  Bradley M Hemminger; Billy Saelim; Patrick F Sullivan
Journal:  Bioinformatics       Date:  2006-01-17       Impact factor: 6.937

8.  Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study.

Authors:  Marvin S Swartz; H Ryan Wagner; Jeffrey W Swanson; T Scott Stroup; Joseph P McEvoy; Mark McGee; Del D Miller; Fred Reimherr; Ahsan Khan; José M Cañive; Jeffrey A Lieberman
Journal:  Psychiatr Serv       Date:  2006-08       Impact factor: 3.084

9.  Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial.

Authors:  Del D Miller; Joseph P McEvoy; Sonia M Davis; Stanley N Caroff; Bruce L Saltz; Miranda H Chakos; Marvin S Swartz; Richard S E Keefe; Robert A Rosenheck; T Scott Stroup; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2005-09-19       Impact factor: 4.939

10.  Genomewide association for schizophrenia in the CATIE study: results of stage 1.

Authors:  P F Sullivan; D Lin; J-Y Tzeng; E van den Oord; D Perkins; T S Stroup; M Wagner; S Lee; F A Wright; F Zou; W Liu; A M Downing; J Lieberman; S L Close
Journal:  Mol Psychiatry       Date:  2008-03-18       Impact factor: 15.992

View more
  17 in total

1.  Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.

Authors:  Stanley N Caroff; Irene Hurford; Janice Lybrand; E Cabrina Campbell
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

Review 2.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

3.  Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.

Authors:  S Mas; P Gassó; A Lafuente; M Bioque; A Lobo; A Gonzàlez-Pinto; M S Olmeda; I Corripio; A Llerena; B Cabrera; J Saiz-Ruiz; M Bernardo
Journal:  Pharmacogenomics J       Date:  2016-06-07       Impact factor: 3.550

Review 4.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 5.  Pharmacogenetics of antipsychotics.

Authors:  Eva J Brandl; James L Kennedy; Daniel J Müller
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

Review 6.  Genetics of Common Antipsychotic-Induced Adverse Effects.

Authors:  Raymond R MacNeil; Daniel J Müller
Journal:  Mol Neuropsychiatry       Date:  2016-05-20

7.  Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia.

Authors:  Renan P Souza; Vincenzo de Luca; Gary Remington; Jeffrey A Lieberman; Herbert Y Meltzer; James L Kennedy; Albert H C Wong
Journal:  Psychopharmacology (Berl)       Date:  2010-04-06       Impact factor: 4.530

Review 8.  Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.

Authors:  Gavin P Reynolds; Olga O McGowan; Caroline F Dalton
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 9.  Perphenazine for schizophrenia.

Authors:  Benno Hartung; Stephanie Sampson; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2015-03-06

Review 10.  Recent Progress in Pharmacogenomics of Antipsychotic Drug Response.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Curr Psychiatry Rep       Date:  2018-03-27       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.